FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083523198> ?p ?o ?g. }

• W2083523198 abstract "The integrin avβ6 promotes migration, invasion and survival of cancer cells, but the biological relevance has yet to be ascertained in breast cancer. Our immunhistochemical analysis of over 2000 breast cancers has revealed that high expression of the protein for the integrin subunit beta6 (β6) is associated with very poor survival (HR = 1.99, P = 2.9×10-6) and increased metastases to distant sites (P = 0·02). This correlation was confirmed at the mRNA level via bioinformatic analysis of the 2000 women in the METABRIC cohort. Furthermore, co-expression of HER2 gave a significantly worse prognosis (HR = 3.43, P = 4×10-12), which we investigated further. We report from in vitro studies that HER2-driven invasion is mediated by αvβ6 in an Akt2-dependent manner. Using the well-tolerated αvβ6-blocking antibody 264RAD in vivo we show that antibody-blockade of this integrin suppressed growth of BT-474 and MCF-7/HER2-18 human breast cancer xenografts similarly to trastuzumab alone (P 264RAD or trastuzumab prolonged survival to a similar degree (14.3% and 33.33% treated mice alive after 100d, respectively, no significant difference) but again, when both drugs were combined 85.7% of mice were alive after 100d, a highly significant response compared with PBS (P Since 70% of women treated with trastuzumab either have, or develop resistance, we suggest combined targeting of αvβ6 and HER2 could provide an important novel therapy for thousands of women with breast cancer. In fact, over 39,000 American women annually (NIH statistics) will develop HER2+ breast cancers for which no specific therapies exist. Our data shows that in excess of 40% of these women with trastuzumab-resistant disease are also likely to express high levels of αvβ6. Our data also suggest that routine determination of the level of expression of αvβ6 on breast cancers would be a valuable clinical tool as it identifies novel high-risk groups of women that require enhanced therapeutic intervention. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-15-01." @default.
• W2083523198 created "2016-06-24" @default.
• W2083523198 creator A5001053254 @default.
• W2083523198 creator A5002323221 @default.
• W2083523198 creator A5008106221 @default.
• W2083523198 creator A5009072377 @default.
• W2083523198 creator A5015496797 @default.
• W2083523198 creator A5018295147 @default.
• W2083523198 creator A5025946229 @default.
• W2083523198 creator A5030581975 @default.
• W2083523198 creator A5037703221 @default.
• W2083523198 creator A5039622637 @default.
• W2083523198 creator A5040948223 @default.
• W2083523198 creator A5042692711 @default.
• W2083523198 creator A5045070080 @default.
• W2083523198 creator A5048632144 @default.
• W2083523198 creator A5051602594 @default.
• W2083523198 creator A5051937736 @default.
• W2083523198 creator A5061882210 @default.
• W2083523198 creator A5070584107 @default.
• W2083523198 creator A5070876778 @default.
• W2083523198 creator A5072162973 @default.
• W2083523198 creator A5072249752 @default.
• W2083523198 creator A5073060262 @default.
• W2083523198 creator A5074278844 @default.
• W2083523198 creator A5074338642 @default.
• W2083523198 creator A5076743192 @default.
• W2083523198 creator A5085300771 @default.
• W2083523198 creator A5087672591 @default.
• W2083523198 creator A5091234611 @default.
• W2083523198 date "2013-12-15" @default.
• W2083523198 modified "2023-09-27" @default.
• W2083523198 title "Abstract P4-15-01: Integrin avb6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy" @default.
• W2083523198 doi "https://doi.org/10.1158/0008-5472.sabcs13-p4-15-01" @default.
• W2083523198 hasPublicationYear "2013" @default.
• W2083523198 type Work @default.
• W2083523198 sameAs 2083523198 @default.
• W2083523198 citedByCount "0" @default.
• W2083523198 crossrefType "proceedings-article" @default.
• W2083523198 hasAuthorship W2083523198A5001053254 @default.
• W2083523198 hasAuthorship W2083523198A5002323221 @default.
• W2083523198 hasAuthorship W2083523198A5008106221 @default.
• W2083523198 hasAuthorship W2083523198A5009072377 @default.
• W2083523198 hasAuthorship W2083523198A5015496797 @default.
• W2083523198 hasAuthorship W2083523198A5018295147 @default.
• W2083523198 hasAuthorship W2083523198A5025946229 @default.
• W2083523198 hasAuthorship W2083523198A5030581975 @default.
• W2083523198 hasAuthorship W2083523198A5037703221 @default.
• W2083523198 hasAuthorship W2083523198A5039622637 @default.
• W2083523198 hasAuthorship W2083523198A5040948223 @default.
• W2083523198 hasAuthorship W2083523198A5042692711 @default.
• W2083523198 hasAuthorship W2083523198A5045070080 @default.
• W2083523198 hasAuthorship W2083523198A5048632144 @default.
• W2083523198 hasAuthorship W2083523198A5051602594 @default.
• W2083523198 hasAuthorship W2083523198A5051937736 @default.
• W2083523198 hasAuthorship W2083523198A5061882210 @default.
• W2083523198 hasAuthorship W2083523198A5070584107 @default.
• W2083523198 hasAuthorship W2083523198A5070876778 @default.
• W2083523198 hasAuthorship W2083523198A5072162973 @default.
• W2083523198 hasAuthorship W2083523198A5072249752 @default.
• W2083523198 hasAuthorship W2083523198A5073060262 @default.
• W2083523198 hasAuthorship W2083523198A5074278844 @default.
• W2083523198 hasAuthorship W2083523198A5074338642 @default.
• W2083523198 hasAuthorship W2083523198A5076743192 @default.
• W2083523198 hasAuthorship W2083523198A5085300771 @default.
• W2083523198 hasAuthorship W2083523198A5087672591 @default.
• W2083523198 hasAuthorship W2083523198A5091234611 @default.
• W2083523198 hasConcept C121608353 @default.
• W2083523198 hasConcept C126322002 @default.
• W2083523198 hasConcept C143998085 @default.
• W2083523198 hasConcept C150903083 @default.
• W2083523198 hasConcept C159654299 @default.
• W2083523198 hasConcept C170493617 @default.
• W2083523198 hasConcept C195687474 @default.
• W2083523198 hasConcept C202751555 @default.
• W2083523198 hasConcept C203014093 @default.
• W2083523198 hasConcept C207001950 @default.
• W2083523198 hasConcept C2779786085 @default.
• W2083523198 hasConcept C2780932548 @default.
• W2083523198 hasConcept C502942594 @default.
• W2083523198 hasConcept C530470458 @default.
• W2083523198 hasConcept C55493867 @default.
• W2083523198 hasConcept C71924100 @default.
• W2083523198 hasConcept C86803240 @default.
• W2083523198 hasConceptScore W2083523198C121608353 @default.
• W2083523198 hasConceptScore W2083523198C126322002 @default.
• W2083523198 hasConceptScore W2083523198C143998085 @default.
• W2083523198 hasConceptScore W2083523198C150903083 @default.
• W2083523198 hasConceptScore W2083523198C159654299 @default.
• W2083523198 hasConceptScore W2083523198C170493617 @default.
• W2083523198 hasConceptScore W2083523198C195687474 @default.
• W2083523198 hasConceptScore W2083523198C202751555 @default.
• W2083523198 hasConceptScore W2083523198C203014093 @default.
• W2083523198 hasConceptScore W2083523198C207001950 @default.
• W2083523198 hasConceptScore W2083523198C2779786085 @default.
• W2083523198 hasConceptScore W2083523198C2780932548 @default.
• W2083523198 hasConceptScore W2083523198C502942594 @default.
• W2083523198 hasConceptScore W2083523198C530470458 @default.
• W2083523198 hasConceptScore W2083523198C55493867 @default.
• W2083523198 hasConceptScore W2083523198C71924100 @default.

• next